Who makes DMPA Sub-cutaneous?

DMPA Sub-cutaneous is developed by Eastern Virginia Medical School.

What development phase is DMPA Sub-cutaneous in?

DMPA Sub-cutaneous is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

DMPA Sub-cutaneous

Eastern Virginia Medical School · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	DMPA Sub-cutaneous
Also known as	Subcutaneous depot medroxyprogesterone acetate
Sponsor	Eastern Virginia Medical School
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
Impact of Contraceptives on Cervico-Vaginal Mucosa (PHASE4)
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods (PHASE1)
Sayana® Press Self-injection Study in Malawi (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DMPA Sub-cutaneous CI brief — competitive landscape report
DMPA Sub-cutaneous updates RSS · CI watch RSS
Eastern Virginia Medical School portfolio CI